New on Advanced Science:
BCR::ABL1 drives malignant transformation of Ph+B-ALL through enhancer reprogramming. Consequently, BCR::ABL1-induced genes are hypersensitive to P300/CBP inhibition. Importantly, enhancer-targeting drugs can improve efficacy of TKIs on Ph+B-ALL cells
doi.org/10.1002/advs...
doi.org
BCR::ABL1‐Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B‐ALL Cells to Enhancer‐Targeting Drugs
Ng et al. show that the BCR::ABL1 kinase that drives the lymphoid leukemia Ph+B-ALL modulates enhancer function by coopting signaling-inducible transcription factors such as MYC, STAT5, and ETV5. BCR...
